HBI-8000

DRUG4 trials

Sponsors

HUYABIO International, LLC.

Conditions

Adult T-Cell Lymphoma (ATL)Breast CancerNon-Hodgkin's LymphomaPeripheral T-Cell Lymphoma (PTCL)

Phase 1

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

WithdrawnNCT02569489

HUYABIO International, LLC.Breast Cancer

Start: 2015-12-31End: 2015-12-31Updated: 2022-07-18

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

CompletedNCT02697552

HUYABIO International, LLC.Non-Hodgkin's Lymphoma

Start: 2014-03-31End: 2016-10-31Updated: 2017-01-12

Phase 2

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

CompletedNCT02953652

HUYABIO International, LLC.Peripheral T-Cell Lymphoma (PTCL)

Start: 2016-11-30End: 2022-02-17Updated: 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

CompletedNCT02955589

HUYABIO International, LLC.Adult T-Cell Lymphoma (ATL)

Start: 2016-11-30End: 2019-11-30Updated: 2024-09-19

Related Papers

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Haematologica2022-10-0651 citations

A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL)

Hematological Oncology2021-06-012 citations

A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUCIDINOSTAT (HBI‐8000) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY ADULT T‐CELL LEUKEMIA‐LYMPHOMA (ATL)

Hematological Oncology2021-06-011 citations

Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results

Blood2016-12-026 citations